<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GATIFLOXACIN</span><br/>(gat-i-flox'a-sin)<br/><span class="topboxtradename">Tequin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">quinolone</span><br/><b>Prototype: </b>Ciprofloxacin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 400 mg tablets; 200 mg/20 mL, 400 mg/40 mL vials; 200 mg/100 mL, 400 mg/200 mL premixed bags</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic quinolone that is a broad spectrum bactericidal agent. Inhibits DNA-gyrase, topoisomerase II, an enzyme necessary
         for bacterial replication, transcription, repair and recombination.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectiveness indicated by normal C&amp;S, WBC counts, and no systemic signs of infection. Effective against methicillin-resistant
         <i>Staphylococcus aureus</i> (MRSA) bacteria infections, penicillin resistant <i>Streptococcus pneumoniae,</i> and <i>Pseudomonas aeruginosa,</i> as well as cocci resistant to other quinolone antimicrobials.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute bacterial exacerbation of chronic bronchitis; acute sinusitis; community-acquired pneumonia; uncomplicated or complicated
         UTI; pyelonephritis; gonorrhea due to susceptible organisms.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to gatifloxacin or other quinolone antibiotics; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; patients with central nervous system disorders including seizures or epilepsy; GI disorders, renal dysfunction;
         hypersensitivity to other medications; concurrent administration of aluminum-containing antacids. Safety and efficacy in children
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Bacterial Exacerbation of Chronic Bronchitis, Complicated</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg q.d. times 5 d<br/><br/><span class="indicationtitle">Complicated UTI, Acute Pyelonephritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg q.d. times 710 d<br/><br/><span class="indicationtitle">Acute Sinusitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg q.d. times 10 d<br/><br/><span class="indicationtitle">Community Acquired Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg q.d. times 714 d<br/><br/><span class="indicationtitle">Uncomplicated UTI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg as a single dose or 200 mg q.d. times 3 d<br/><br/><span class="indicationtitle">Uncomplicated Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg as a single dose<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at least 4 h before or after an aluminum- or magnesium-containing antacid, or iron-containing products.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute a 200 mg/20 mL or 400 mg/40 mL single-use vial by adding contents of the vial to either 80 mL or 160 mL, respectively,
                  of D5W, NS, D5/NS, RL or other compatible IV solution. Resulting IV solution contains 2 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give a single dose over at least 60 min. Avoid rapid infusion.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b> Amphotericin B,</b>
<b>amphotericin B cholesteryl sulfate,</b>
<b>cefoperazone,</b>
<b>cefonicid,</b>
<b>cefoxitin,</b>
<b>diazepam,</b>
<b>furosemide,</b>
<b>heparin,</b>
<b>mezlocillin,</b>
<b>phenytoin,</b>
<b>piperacillin,</b>
<b>piperacillin/tazobactam,</b>
<b>potassium phosphate,</b>
<b>vancomycin.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Headache, allergic reactions, chills, fever; back pain, chest pain. <span class="typehead">CNS:</span> Dizziness, abnormal dreams, insomnia, paresthesia, tremor, vasodilatation, vertigo. <span class="typehead">CV:</span> Palpitation; peripheral edema. <span class="typehead">GI:</span> Nausea, diarrhea, abdominal pain, constipation, dyspepsia, glossitis, oral moniliasis, stomatitis, vomiting. <span class="typehead">Respiratory:</span> Dyspnea, pharyngitis. <span class="typehead">Skin:</span> Rash, sweating. <span class="typehead">Urogenital:</span> Vaginitis, dysuria, hematuria. <span class="typehead">Special Senses:</span> Abnormal vision, taste perversion, tinnitus. <span class="typehead">Metabolic:</span> Hyperglycemia, hypoglycemia. <span class="typehead">Other:</span> Cartilage erosion. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause false positive on <span class="alt">opiate screening tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases elimination of <b>gatifloxacin;</b>
<b>ferrous sulfate,</b>
<small>ALUMINUM</small>- or <small>MAGNESIUM</small>-<small>CONTAINING ANTACIDS</small> reduce absorption of <b>gatifloxacin;</b>
<b>gatifloxacin</b> may cause slight increase in <b>digoxin</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 96% absorbed from GI tract. <span class="typehead">Peak:</span> 12 h PO. <span class="typehead">Distribution:</span> 20% protein bound. <span class="typehead">Metabolism:</span> Minimal metabolism (Elimination: Primarily excreted in urine. <span class="typehead">Half-Life:</span> 714 h (up to 3540 h in severe renal failure). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of CNS disturbance especially with history of cerebrovascular disease or seizures.</li>
<li>Lab tests: C&amp;S prior to initiation of therapy; WBC with differential.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Monitor for changes in digoxin blood levels with coadministered drugs.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that increased risk of seizures are associated with drug use in patient with history of seizures.</li>
<li>Report unexplained dizziness or problems with balance, severe diarrhea, skin rash, mental status changes.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>